
Preclinical studies demonstrate potential of zelquistinel in autism
Robust efficacy in several preclinical models supports high translational potential of zelquistinel in autism and reflects broader opportunity across synaptic dysfunction disorders. Gate Neurosciences has announced the publication of new peer-reviewed research demonstrating the therapeutic potential of zelquistinel (GATE-251) to address symptoms of autism spectrum disorder… Read More


